Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial

Cell Therapy Transplant Canada

doi:10.1016/S2352-3026(19)30220-0

Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial

Cell Therapy Transplant Canada

Pharmacology, Toxicology and Pharmaceutics

Research output: Contribution to journal › Article › peer-review

70 Citations (Scopus)

Original language	English
Pages (from-to)	e100-e111
Journal	The Lancet Haematology
Volume	7
Issue number	2
DOIs	https://doi.org/10.1016/S2352-3026(19)30220-0
Publication status	Published - Feb 2020

ASJC Scopus Subject Areas

Hematology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S2352-3026(19)30220-0

Fingerprint

Dive into the research topics of 'Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial'. Together they form a unique fingerprint.

Cite this

Cell Therapy Transplant Canada (2020). Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. The Lancet Haematology, 7(2), e100-e111. https://doi.org/10.1016/S2352-3026(19)30220-0

Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. / Cell Therapy Transplant Canada.
In: The Lancet Haematology, Vol. 7, No. 2, 02.2020, p. e100-e111.

Research output: Contribution to journal › Article › peer-review

Cell Therapy Transplant Canada 2020, 'Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial', The Lancet Haematology, vol. 7, no. 2, pp. e100-e111. https://doi.org/10.1016/S2352-3026(19)30220-0

Cell Therapy Transplant Canada. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. The Lancet Haematology. 2020 Feb;7(2):e100-e111. doi: 10.1016/S2352-3026(19)30220-0

Cell Therapy Transplant Canada. / Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors : final analysis of a randomised, open-label, multicentre, phase 3 trial. In: The Lancet Haematology. 2020 ; Vol. 7, No. 2. pp. e100-e111.

@article{852a15bdea7347cf873979cb28946266,

title = "Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial",

author = "{Cell Therapy Transplant Canada} and Irwin Walker and Tony Panzarella and Stephen Couban and Felix Couture and Gerald Devins and Mohamed Elemary and Genevi{\`e}ve Gallagher and Holly Kerr and John Kuruvilla and Lee, {Stephanie J.} and John Moore and Thomas Nevill and Gizelle Popradi and Jean Roy and Schultz, {Kirk R.} and David Szwajcer and Cynthia Toze and Ronan Foley",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Ltd",

year = "2020",

month = feb,

doi = "10.1016/S2352-3026(19)30220-0",

language = "English",

volume = "7",

pages = "e100--e111",

journal = "The Lancet Haematology",

issn = "2352-3026",

publisher = "Lancet Publishing Group",

number = "2",

}

TY - JOUR

T1 - Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors

T2 - final analysis of a randomised, open-label, multicentre, phase 3 trial

AU - Cell Therapy Transplant Canada

AU - Walker, Irwin

AU - Panzarella, Tony

AU - Couban, Stephen

AU - Couture, Felix

AU - Devins, Gerald

AU - Elemary, Mohamed

AU - Gallagher, Geneviève

AU - Kerr, Holly

AU - Kuruvilla, John

AU - Lee, Stephanie J.

AU - Moore, John

AU - Nevill, Thomas

AU - Popradi, Gizelle

AU - Roy, Jean

AU - Schultz, Kirk R.

AU - Szwajcer, David

AU - Toze, Cynthia

AU - Foley, Ronan

PY - 2020/2

Y1 - 2020/2

UR - http://www.scopus.com/inward/record.url?scp=85078261688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85078261688&partnerID=8YFLogxK

U2 - 10.1016/S2352-3026(19)30220-0

DO - 10.1016/S2352-3026(19)30220-0

M3 - Article

C2 - 31958417

AN - SCOPUS:85078261688

SN - 2352-3026

VL - 7

SP - e100-e111

JO - The Lancet Haematology

JF - The Lancet Haematology

IS - 2

ER -

Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial

ASJC Scopus Subject Areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this